A systematic review of the clinical pharmacokinetics of fluconazole in healthy and diseased populations.

Authors

Tahir Saleem, Khadija Ameen, Muhammad Fawad Rasool, Faleh Alqahtani

Published in

Expert review of anti-infective therapy. Oct 02, 2026. Epub Oct 02, 2026.

Abstract

Fluconazole is a triazole antifungal agent commonly used to treat both systemic and superficial fungal infections. This comprehensive review aims to collate all published pharmacokinetic (PK) data on fluconazole in healthy and diseased subjects.
A systematic search of Google Scholar, PubMed, and the Cochrane Library identified 40 clinical PK studies of fluconazole that met inclusion criteria.
In healthy volunteers, oral fluconazole (100 mg) achieved a maximum plasma concentration (C_max) of 2.184 ± 0.427 µg/mL and peak time (T_max) of 2.6 ± 1.4 h, while IV administration produced a steady-state area under curve from 0 to t (AUC_0-t) of 608 ± 115.4 µg.h/mL. In diseased populations, fluconazole PK varied according to the underlying clinical condition, including renal and hepatic impairment, peritoneal dialysis, and neoplastic disease. Patients with moderate renal impairment following IV administration exhibited a higher C_max (15.7 ± 2 ug/mL) than those with severe renal impairment (12.5 ± 1.24 ug/mL). Following a 150 mg oral dose, AUC_0-t was higher under fasting than fed conditions (123.600 ± 16.760 vs. 113.000 ± 15.339 µg.h/mL).
This systematic review compiles fluconazole PK data to support dose optimization in renal impairment and minimize toxicity and drug-drug interactions.

PMID:
42825471
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.